1. 衛生福利部國民健康署. 罕見疾病通報個案統計表 (107 年 5 月至 108 年 4 月). https://www.hpa.gov.tw/Pages/TopicList.aspx?nodeid=1559. Published 2019. Accessed May 22, 2019.
2. 台灣氣喘衛教學會. 遺傳性血管性水腫台灣診療指引 (第六版).
http://www.asthma-edu.org.tw/asthma/member1_b.aspx?itemID=2019051309 2455. Published 2019. Accessed May 22, 2019.
3. 衛生福利部國民健康署. 公告罕見疾病名單暨 ICD-10-CM 編碼一覽表.
https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=43&pid=1065. Published 2019. Accessed May 22, 2019.
4. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy 2018; 73(8): 1575-1596.
5. Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clinical and experimental immunology 2014; 177(2): 544-553.
6. 衛生福利部. Firazyr 適用罕見疾病防治及藥物法之藥物審議委員會同意 認定函; 2018.
7. Shire Orphan Therapies L. FIRAZYR® (icatibant) 藥品仿單.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022150s007lbl.pd f. Published 2015. Accessed May 28, 2019.
8. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health. ATC/DDD Index (B06AC02).
https://www.whocc.no/atc_ddd_index/. Published 2018. Accessed May 28, 2019.
9. 衛生福利部食品藥物管理署. 西藥、醫療器材、化粧品許可證查詢 (ATC:
B06AC). . https://www.fda.gov.tw/mlms/H0001.aspx. Published 2019.
Accessed May 28, 2019.
10. 衛生福利部中央健康保險署. 健保用藥品項查詢. Published 2019.
Accessed May 28, 2019.
11. CSL Behring GmbH. Berinert® (C1 esterase inhibitor [human]) 藥品仿單.
http://labeling.cslbehring.com/PI/US/Berinert/EN/Berinert-Prescribing-Inform ation.pdf. Published 2017. Accessed May 28, 2019.
12. Dyax Corp. Kalbitor® (ecallantide) 藥品仿單.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pd f. Published 2014. Accessed May 28, 2019.
仿單. https://www.fda.gov/media/89212/download. Published 2014. Accessed May 28, 2019.
14. Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation: icatibant (Firazyr- Shire Human Genetics Therapies [Canada] Inc.) Indication: Hereditary Angioedema (Acute Attacks)).
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0375_F irazyr_Dec-23-14.pdf. Published 2014. Accessed May 28, 2019.
15. PBAC. March 2012 PBAC Outcomes - Positive Recommendations: Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr®
Shire Australia Pty Ltd.
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outc omes/2012-03/positive-recommendations. Published 2012. Accessed May 09, 2019.
16. PBAC. Icatibant: Injection 30 mg (as acetate)in 3 mL single use pre-filled syringe; Firazyr® .
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-07/icatibant-psd-july-2017. Published 2017. Accessed May 08, 2019.
17. PBAC. Public summary document: Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr® Shire Australia Pty Ltd.
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-11/icatibant-psd-november-2016. Published 2016. Accessed May 09, 2019.
18. PBAC. Public summary document: Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr® Shire Australia Pty Ltd.
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2011-07/Ic atibant_FIRAZYR_Shire_PSD_7-6_2011-07_FINAL.pdf. Published 2011.
Accessed May 09, 2019.
19. PBAC. Public summary document: Icatibant, injection, 30 mg in 3 mL (as acetate), single use pre-filled syringe, Firazyr® Shire Australia Pty Ltd.
http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2010-07/I catibant_FIRAZYR_Shire.pdf. Published 2010. Accessed May 09, 2019.
20. SMC. icatibant acetate, 30mg, solution for injection in pre-filled syringe (Firazyr® ) SMC No 1332/18.
https://www.scottishmedicines.org.uk/media/3405/icatibant-acetate-firazyr-ab breviated-final-april-2018-for-website.pdf. Published 2018. Accessed May 08, 2019.
21. SMC. icatibant acetate, 30mg, solution for injection in pre-filled syringe (Firazyr® ) SMC No 476/08.
https://www.scottishmedicines.org.uk/medicines-advice/icatibant-firazyr-resub
mission-47608/. Published 2012. Accessed May 08, 2019.
22. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Annals of allergy, asthma &
immunology : official publication of the American College of Allergy, Asthma,
& Immunology 2011; 107(6): 529-537.
23. Lumry WR, Farkas H, Moldovan D, et al. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. International archives of allergy and immunology 2015; 168(1):
44-55.
24. Bas M, Greve J, Hoffmann TK, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013; 68(11): 1452-1459.
25. Shire Orphan Therapies L. Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) (FAST2).
https://clinicaltrials.gov/ct2/show/results/NCT00500656. Published 2015.
Accessed May 19, 2019.
26. NHS Commissioning Board. Treatment of Acute Attacks in Hereditary Angioedema(Adult).
https://www.england.nhs.uk/wp-content/uploads/2018/07/Treatment-of-acute-attacks-in-hereditary-angiodema-adult.pdf. Published April 2013. Accessed May 19, 2019.
27. Blasco, A.J., et al., Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain. Health Econ Rev, 2013. 3(1): p. 2.
28. Federici, C., et al., Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. BMJ Open, 2018. 8(7): p. e022291.
29. 徐世達, 遺傳性血管性水腫 (HAE) 台灣診療指引簡版. 台灣氣喘衛教學 會會刊, 2017(46): p. 24-28.
30. Lumry, W.R., Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care, 2013. 19(7 Suppl):
p. s103-10.
31. Lei, W.T., et al., Type I hereditary angioedema in Taiwan -- clinical, biological features and genetic study. Asian Pac J Allergy Immunol, 2011. 29(4): p.
327-31.
32. Xu, Y.Y., et al., Clinical features of hereditary angioedema in Chinese patients:
new findings and differences from other populations. Eur J Dermatol, 2013.
23(4): p. 500-4.
33. Wilson, D.A., et al., Economic costs associated with acute attacks and long-term management of hereditary angioedema. Annals of Allergy, Asthma
& Immunology, 2010. 104(4): p. 314-320. e2.
34. Floccard, B., et al., An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core evidence, 2012. 7: p. 105.
附錄
附錄表一 療效評估文獻搜尋記錄
資料庫 查詢日期 # 關鍵字 篇數
PubMed 2019/5/14 1 (("therapy"[Subheading] OR "therapy"[All Fields] OR "treatment"[All Fields] OR
"therapeutics"[MeSH Terms] OR
"therapeutics"[All Fields]) AND ("angioedemas, hereditary"[MeSH Terms] OR
("angioedemas"[All Fields] AND
"hereditary"[All Fields]) OR "hereditary angioedemas"[All Fields] OR ("hereditary"[All Fields] AND "angioedema"[All Fields]) OR
"hereditary angioedema"[All Fields])) AND ("icatibant"[Supplementary Concept] OR
"icatibant"[All Fields]) AND Clinical Trial, Phase III[ptyp]
10
2 (("therapy"[Subheading] OR "therapy"[All Fields] OR "treatment"[All Fields] OR
"therapeutics"[MeSH Terms]
1
3 (("therapy"[Subheading] OR "therapy"[All Fields] OR "treatment"[All Fields] OR
"therapeutics"[MeSH Terms] OR
"therapeutics"[All Fields]) AND ("angioedemas, hereditary"[MeSH Terms] OR
("angioedemas"[All Fields] AND
"hereditary"[All Fields]) OR "hereditary angioedemas"[All Fields] OR ("hereditary"[All Fields] AND "angioedema"[All Fields]) OR
"hereditary angioedema"[All Fields])) AND ("icatibant"[Supplementary Concept] OR
"icatibant"[All Fields]) AND systematic[sb]
4
4 HAE[All Fields] AND
("icatibant"[Supplementary Concept] OR
"icatibant"[All Fields]) AND Meta-Analysis[ptyp]
1
Embase 2019/05/14 1 ('hereditary angioedema'/exp OR 'hereditary angioedema') AND icatibant:jt
0
附錄表二 經濟文獻搜尋紀錄
資料庫 查詢日期 關鍵字 篇數
Pubmed 2019/5/10 #1 hereditary angioedema [MeSH Terms]
#2 icatibant OR Firazyr [All fields]
#3 cost AND cost analysis [All fields]
#4 #1 AND #2 AND #3
1,859 1,328 308,242 9 Embase 2019/5/10 #1 hereditary angioedema [All fields]
#2 icatibant[All fields]
#3 cost AND cost analysis[ti,ab]
#4 #1 AND #2 AND #3
19,667 2,916 333,915 34 Cochrane
Library
2019/5/10 #1 hereditary angioedema [ti,ab,kw]
#2 icatibant [ti,ab,kw]
#3 “cost analysis” [ti,ab,kw]
#4 #1 AND #2 AND #3
283 91 33,275 0